Discovery of an Orally Available Potent ER Aminopeptidase 1 (ERAP1) Inhibitor That Enhances Antitumor Responses and Limits Inflammatory AutoimmunityIn Vivo

Post time 7 day(s) ago

journal：Journal of Medicinal Chemistry

Authors：Christopher P. Tinworth; Justyna Wojno-Picon; Michael Adam; Stephan Gade; Ashley P. Hancock; David J. Hirst; Jonathan P. Hutchinson; Semra Kitchen; Despoina Koumantou; Jonathan Lea; Stephanie Lehmann; John Liddle; Richard Lonsdale; Margarete Neu; Leng Nickels; Alex Phillipou; James E. Rowedder; Paul Rowland; Jessica L. Schneck; Paul Scott-Stevens; Hester Sheehan; Michael Steidel; Chloe L. Tayler; Ioannis Temponeras; Kevin Thang; David F. Tough; Giovanni Vitulli; Ian D. Wall; Robert J. Young; Nico Zinn; Simon Peace; Efstratios Stratikos

Published date：2026-7-9

DOI：10.1021/acs.jmedchem.6c00029

PDF link：https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6c00029

Article link：https://doi.org/10.1021/acs.jmedchem.6c00029

Article Source：American Chemical Society (ACS)。

Remark：

Post time 7 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[ACS] Discovery of an Orally Available Potent ER Aminopeptidase 1 (ERAP1) Inhibitor That Enhances Antitumor Responses and Limits Inflammatory AutoimmunityIn Vivo

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[ACS] Discovery of an Orally Available Potent ER Aminopeptidase 1 (ERAP1) Inhibitor That Enhances Antitumor Responses and Limits Inflammatory AutoimmunityIn Vivo Copy

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[ACS] Discovery of an Orally Available Potent ER Aminopeptidase 1 (ERAP1) Inhibitor That Enhances Antitumor Responses and Limits Inflammatory AutoimmunityIn Vivo